MPM Bioimpact LLC Acquires 2,926,002 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

MPM Bioimpact LLC grew its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 51.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,567,896 shares of the company's stock after purchasing an additional 2,926,002 shares during the quarter. Compass Therapeutics comprises about 1.8% of MPM Bioimpact LLC's investment portfolio, making the stock its 27th largest position. MPM Bioimpact LLC owned 6.23% of Compass Therapeutics worth $12,423,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Barclays PLC boosted its stake in Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company's stock worth $314,000 after purchasing an additional 112,614 shares in the last quarter. SG Americas Securities LLC boosted its stake in Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock worth $573,000 after purchasing an additional 356,352 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Compass Therapeutics by 25.2% in the fourth quarter. Renaissance Technologies LLC now owns 278,600 shares of the company's stock worth $404,000 after purchasing an additional 56,000 shares in the last quarter. Bleakley Financial Group LLC boosted its stake in Compass Therapeutics by 250.7% in the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company's stock worth $58,000 after purchasing an additional 28,589 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Compass Therapeutics by 512.5% during the fourth quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company's stock worth $395,000 after acquiring an additional 227,864 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company's stock.

Insider Transactions at Compass Therapeutics

In related news, insider Jonathan Anderman purchased 20,000 shares of Compass Therapeutics stock in a transaction that occurred on Monday, April 7th. The stock was purchased at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the transaction, the insider now owns 21,000 shares of the company's stock, valued at approximately $32,340. This trade represents a 2,000.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. 29.80% of the stock is owned by insiders.

Compass Therapeutics Stock Performance

NASDAQ:CMPX traded up $0.08 on Friday, reaching $2.10. The company's stock had a trading volume of 1,104,624 shares, compared to its average volume of 913,989. Compass Therapeutics, Inc. has a 1-year low of $0.77 and a 1-year high of $4.08. The firm has a market cap of $290.39 million, a PE ratio of -5.68 and a beta of 1.40. The business's 50-day moving average price is $1.94 and its two-hundred day moving average price is $2.10.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.12). As a group, sell-side analysts expect that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Analysts Set New Price Targets

CMPX has been the subject of a number of recent research reports. Piper Sandler initiated coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 target price for the company. D. Boral Capital restated a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research report on Monday, April 28th. Leerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. HC Wainwright restated a "buy" rating and set a $24.00 target price on shares of Compass Therapeutics in a research report on Monday, April 21st. Finally, Guggenheim dropped their target price on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $13.13.

Compass Therapeutics Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.